Wednesday, October 14, 2026

Venture Capital & Funding

2 articles

Venture Capital Creates 68 Unicorns in Q1 2026, Matching 58% of 2025 Full-Year Total

The venture capital market generated 68 new unicorns in Q1 2026, already surpassing 2024's annual count of 117 and approaching 2025's 187. February 2026 recorded the highest venture funding levels on record, with specialized healthcare and biotech firms leading strategic deployments alongside strong exits from generalist portfolios.

LM Salvado•Mar 19, 2026

Jaunt Air Mobility Faces Capital Runway Crisis as eVTOL Certification Costs Mount

Jaunt Air Mobility confronts high-probability capital depletion before commercialization, threatening its position in the advanced air mobility sector. The eVTOL manufacturer must raise additional funds amid challenging market conditions for aerospace startups. The capital crunch reflects broader funding pressures across the electric aviation industry.

ViaNews Editorial Team (Finance)•Mar 1, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com